671
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials

, , , , , , , , & show all
Article: 2329240 | Received 04 Dec 2023, Accepted 05 Mar 2024, Published online: 28 Apr 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.